Coronary Stent Restenosis in Patients Treated With Cilostazol
Top Cited Papers
- 1 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (18) , 2826-2832
- https://doi.org/10.1161/circulationaha.104.530097
Abstract
Background— Restenosis after implantation of coronary artery stents remains a significant clinical problem. We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries.Keywords
This publication has 22 references indexed in Scilit:
- Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapyPublished by Elsevier ,2004
- A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stentsThe Lancet, 2004
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Systemic drug therapy for restenosis: "déjà vu all over again".Circulation, 2002
- Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) TrialCirculation, 2002
- Predictive Factors of Restenosis After Coronary Stent PlacementJournal of the American College of Cardiology, 1997
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994